# Imaging Biometrics Awarded Patent for No-Contrast MRI Exams

For Immediate Release

Elm Grove, WI, June 23, 2021 – IQ-AI subsidiary Imaging Biometrics (IB) was awarded a U.S. patent for its artificial intelligence (AI) software technology that eliminates the need for gadolinium-based contrast agents (GBCAs) in medical imaging exams. A zero-dose exam potentially offers remarkable benefits which include a more comfortable patient experience, more productive radiology departments, and reduced risks associated from the long-term, albeit uncertain, side effects of repeated GBCA use.

The fully automated AI technology, called IB Zero G™, accepts non-contrast medical images as inputs and produces a synthetic image series that mimics contrast-enhanced images of comparable diagnostic quality. Currently in the investigational stage, IB Zero G is compatible with all magnetic resonance imaging (MRI) scanner platforms.

Standard Contrast   **Zero Contrast**

Injected intravenously, GBCAs improve diagnostic interpretation of MR imaging by highlighting abnormal areas of internal tissues and structures. Gadolinium, a heavy metal, has special paramagnetic properties which make it useful as a contrast agent. However, gadolinium can stay in a body for years, introducing potential safety and liability concerns for patients and healthcare institutions. While there are no known long-term adverse side effects from retained gadolinium in most patients, certain patients are at higher risk of adverse side effects after receiving GBCAs. IB Zero G offers an extremely attractive alternative for these patients and healthcare providers.

By eliminating the need to acquire a contrast-enhanced series, IB Zero G means less time in the scanner for patients. And for healthcare systems, IB Zero G provides increased scanner availability and a reduction in gadolinium expense.

"This patent underscores the major impact AI applications can have in healthcare," said Michael Schmainda, CEO of IB. "IB Zero G has the potential to significantly disrupt routine clinical workflows on a global basis and help millions of patients receive higher quality and safer MR exams," Schmainda added.

ABOUT Imaging Biometrics, LLC

Imaging Biometrics®, LLC, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.